Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, ...

Recent health news highlights include high costs of weight-loss drugs like Wegovy, Septerna's strong Nasdaq debut, ...

The gross proceeds from the offering are expected to be $288.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Septerna Inc. shares rose 19% in their trading debut after the biotechnology company raised $288 million in an enlarged ...

Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the ...

Global stocks were trading higher on Friday, although they were set for a weekly loss amid US election jitters, while oil ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

The HY primary was very active on Thursday with five offerings totaling US$4.05bn, lifting weekly HY issuance to US$6.895bn and October HY volume to US$19.63bn, according to IFR.

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...